Pharmesis Intl (BFK) Annual Reports

The Company was incorporated in Singapore on 29 September 2003 under the name

of Sinopharm Pte Ltd and it changed its name to Pharmesis International Pte Ltd

on 16 April 2004. It adopted its current name on 30 August 2004.

Pharmesis specializes in the manufacture of pharmaceutical products, including

western medicine and Traditional Chinese Medicine (“TCM’’).

Under its two subsidiaries, Kinna Pharm and Longlife, it specializes in the

manufacturing of pharmaceutical products in the form of tablets, granules,

pills, etc, including TCM formulated products for the treatment of illnesses

relating to the liver and gall bladder. Its two main products are ATT tablets

and Gansu granules. Additionally, its business also includes the research and

development, production, sale and marketing of pharmaceutical products. These

pharmaceutical products are sold in China and they include western medicine

products under the “?? ” brand, while its TCM formulated products are sold

under the “???? ” brand.

Leveraging its research and development capabilities and in-house expertise in

pharmaceutical products for the treatment of illnesses relating to the liver

and gall bladder, Pharmesis has successfully obtained the license to produce

ATT tablets in China. Similarly, it is the only Group with the right to produce

Gansu granules from Ganhuangcao in China.

With sales and marketing network of approximately 900 sales personnel across

China, its products can be found in 2,000 hospitals in many cities within

China.

The Group's two production facilities are located in Chengdu and Gulin, China.